Spots Global Cancer Trial Database for Erlotinib and Sunitinib in NSCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Erlotinib and Sunitinib in NSCLC
Official Title: Phase I Study of Erlotinib and Sunitinib in Non-small Cell Lung Cancer
Study ID: NCT00581789
Conditions
Interventions
Study Description
Brief Summary: * To determine the safety and maximally tolerated dose of sunitinib plus erlotinib in patients with non-small cell lung cancer (NSCLC). * To determine response to sunitinib plus erlotinib in patients with non-small cell lung cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Wisconsin Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States
Contact Details
Name: Anne Traynor, MD
Affiliation: University of Wisconsin, Madison
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
